Clinical Trials: More Diversity, Better Outcomes
- Patients from different racial and ethnic groups can respond differently to breast cancer treatments, but most trials still underrepresent non-Caucasian patients, limiting how broadly results can be applied.
- Time, transportation, childcare, strict eligibility criteria, and mistrust in the medical system all make trial participation harder. Overcoming these obstacles requires education, logistical support, and flexibility.
- Early community engagement and inclusive trial design can help patients access promising treatments sooner while advancing more breast cancer care for all.
Race, ethnicity, and representation in global clinical trials play a critical role in improving breast cancer treatment for everyone. Research has shown that patients from different racial and ethnic backgrounds can respond differently to chemotherapy and experience variations in side effects and outcomes. Yet despite these differences, the vast majority of participants in large breast cancer trials remain Caucasian—raising important questions about how well trial results apply to more diverse patient populations.
According to Dr. Francisco Esteva, a breast oncologist at Northwell Health in New York, gaps in trial enrollment make it harder to understand why certain groups, such as Black women with triple-negative breast cancer, often experience worse outcomes. Without broad participation, researchers are left with theories instead of clear answers. While progress is being made, the field is still not as representative as it needs to be.
Clinicians point to multiple barriers such as strict eligibility criteria, transportation challenges, childcare needs, time constraints, and lingering mistrust of the medical system.
Dr. Maysa Abu-Khalaf, a medical oncologist specializing in breast cancer, emphasizes that addressing these issues requires practical support, such as:
- Explaining the rationale for trials to patients
- Helping with logistics
- Making participation easier for patients juggling complex lives
Building trust is also essential. Dr. Kristina Fanucci, a breast oncologist at Dana-Farber Cancer Institute, notes that community engagement must start long before a trial is offered, fostering confidence in research and the medical system as a whole.
Ultimately, increasing diversity in clinical trials benefits everyone. Patients gain earlier access to promising therapies, and the entire breast cancer community moves closer to more equitable, effective care.
